Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | LDHA | P00338 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28180679 | 0.98 | APLNR (0.50) | APLNRKMT2APLCG1HTTLDHA | |
| SCHEMBL6766191 | 0.84 | POLB (0.45) | KMT2APLCG1MEN1POLB | |
| SCHEMBL2717301 | 0.83 | KMT2A (0.57) | APLNRKMT2APLCG1HTTIDO1 | |
| SCHEMBL8474031 | 0.82 | CA2 (0.41) | KMT2ACA12CA1CA2CA5A | |
| SCHEMBL30496480 | 0.81 | PKM (0.56) | APLNRKMT2APLCG1HTTIDO1 | |
| Hydrochloric Acid SCHEMBL27633192 | 0.81 | KMT2A (0.55) | APLNRKMT2APLCG1HTTIDO1 | |
| SCHEMBL294919 | 0.81 | APLNR (0.53) | APLNRKMT2APLCG1HTTIDO1 | |
| SCHEMBL2377998 | 0.81 | APLNR (0.58) | APLNRKMT2APLCG1HTTIDO1 | |
| SCHEMBL3237396 | 0.81 | PKM (0.56) | APLNRKMT2APLCG1HTTIDO1 | |
| SCHEMBL3237393 | 0.81 | KMT2A (0.55) | APLNRKMT2APLCG1HTTIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 287 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106983671-B | Sunscreen agents containing titanium dioxide | 拜尔斯道夫股份有限公司 | 2021-06-08 | — | — | CN | claimed |
| CN-107028777-B | Sunscreen agents containing titanium dioxide | 拜尔斯道夫股份有限公司 | 2021-06-08 | — | — | CN | claimed |
| US-7619095-B2 | Process for the preparation of indolone derivative | ALEMBIC LIMITED (IN) | 2009-11-17 | — | — | US | claimed |
| EP-1848691-B1 | PROCESS FOR THE PREPARATION OF INDOLONE DERIVATIVE | ALEMBIC LTD (IN) | 2009-11-11 | — | — | EP | claimed |
| US-20080262244-A1 | Process for the Preparation of Indolone Derivative | ALEMBIC LIMITED (IN) | 2008-10-23 | — | — | US | claimed |
| EP-1359909-B1 | TRIPTOLIDE PRODRUGS FOR ANTI-CANCER THERAPY | PHARMAGENESIS INC (US) | 2008-08-27 | — | — | EP | claimed |
| EP-1848691-A1 | PROCESS FOR THE PREPARATION OF INDOLONE DERIVATIVE | Alembic Limited (IN) | 2007-10-31 | — | — | EP | claimed |
| WO-2006123356-A1 | PROCESS FOR THE PREPARATION OF INDOLONE DERIVATIVE | ALEMBIC LIMITED (IN) | 2006-11-23 | — | — | WO | claimed |
| EP-0255134-B1 | CARBOSTYRIL DERIVATIVES AND SALTS THEREOF, PROCESS FOR PREPARING THEM, AND CARDIOTONIC COMPOSITION CONTAINING SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-03-03 | — | — | EP | claimed |
| US-20250333400-A1 | CERTAIN PLADIENOLIDE COMPOUNDS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2025-10-30 | — | — | US | disclosed |
| US-20240368140-A1 | CERTAIN PLADIENOLIDE COMPOUNDS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-11-07 | — | — | US | disclosed |
| US-20240350484-A1 | METHODS OF USING SPLICING MODULATORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-10-24 | — | — | US | disclosed |
| EP-3801523-B1 | SPLICING MODULATORS | EISAI R&D MAN CO LTD (JP) | 2024-09-11 | — | — | EP | disclosed |
| EP-4400492-A1 | ACRIDINE COMPOUND | OSAKA UNIVERSITY (JP) | 2024-07-17 | — | — | EP | disclosed |
| US-4468402-A | Carbostyril derivatives, process for producing the same and cardiotonic compositions containing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-08-28 | — | — | US | disclosed |
| EP-0115334-A1 | Benzo-heterocyclic compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-08-08 | — | — | EP | disclosed |
| US-4454130-A | CARDIOTONIC, HYPOTENSIVE AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-06-12 | — | — | US | disclosed |
| EP-0109653-A2 | Process for preparing urokinase complex | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-05-30 | — | — | EP | disclosed |
| US-4435404-A | ANTICOAGULANTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-03-06 | — | — | US | disclosed |
| US-4415572-A | CARDIOTONIC AND INOTROPIC AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1983-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368140-A1 | CERTAIN PLADIENOLIDE COMPOUNDS AND METHODS OF USE | PLAAT5, PLAAT3, PLAAT4 | APLNR 1552/4885KMT2A 3600/4885PLCG1 364/4885 |
| US-20250333400-A1 | CERTAIN PLADIENOLIDE COMPOUNDS AND METHODS OF USE | SNRPE, SNRPB2, DDX21 | APLNR 2767/4885KMT2A 2538/4885PLCG1 522/4885 |
| US-20240350484-A1 | METHODS OF USING SPLICING MODULATORS | SF3B1, RBM17, SF3B5 | APLNR 938/4885KMT2A 1838/4885PLCG1 1868/4885 |
| US-20080262244-A1 | Process for the Preparation of Indolone Derivative | HTR3C, HTR3B, HTR1B | APLNR 4844/4885KMT2A 1799/4885PLCG1 2369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.